Roche to acquire Swiss antibody-specialist GlycArt

Roche Holding plans to buy GlycArt Biotechnology, a Swiss biotech company that specializes in enhancing the efficacy of antibodies. Roche will pay about CHF 235 million in cash for the outstanding stock of privately held GlycArt, which has three monoclonal 1 antibody drugs in preclinical trials for cancer. Monoclonal antibodies are man-made duplicates of proteins used by the immune system.

- read this story from AFX for more

PLUS: Meanwhile, Roche's first-half net profit declines as sales rise. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.